Latest news

Debiopharm International SA to present the latest findings on Debio 1450 at ECCMID

Debiopharm International SA has won its Patent Infringement Suit for Elplat® against Nippon Kayaku Co., Ltd.

Debiopharm International SA and EORTC announce a collaboration to investigate Triptorelin for treatment of Salivary Gland Cancers

Debiopharm International SA and Arbor Pharmaceuticals, LLC announce their US commercialization partnership for Triptorelin in Central Precocious Puberty

United Laboratories Inc. and Debiopharm International SA announce the launch of Pamorelin® LA in the Philippines

Challenge Debiopharm Inartis: appel à projets

EMA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer

Debiopharm International SA’s partner Yakult Honsha Co, Ltd. announces Elplat® approbation in gastric cancer in Japan

Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143…